Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*

202198 citationsJournal Articlebronze Open Access

Authors

Risankizumab demonstrated a favourable safety profile over short- and long-term treatment in patients with moderate-to-severe psoriasis.

Published in: British Journal of Dermatology

Volume 186, Issue 3, pp. 466-475

Field-Weighted Citation Impact: 5.32